Development of immunoadjuvants for immunotherapy of cancer

International Immunopharmacology

Volumn 1, Issue 7, 2001, Pages 1249-1259

  Azuma, Ichiro ^a   Seya, Tsukasa ^b  

^a HAKODATE NATIONAL COLLEGE OF TECHNOLOGY   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Cancer immunotherapy; Cell wall skeleton (CWS); CpG repeats; Dendritic cells Macrophages; Innate immunity; MDP; Mycobacterial cell fractions; TDM; Toll like receptor

Indexed keywords

CELL WALL SKELETON; CORD FACTOR; FREUND ADJUVANT; IMMUNOLOGICAL ADJUVANT; MURAMYL DIPEPTIDE DERIVATIVE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ANTIGEN PRESENTATION; CANCER; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CLINICAL TRIAL; CPG ISLAND; DENDRITIC CELL; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INFECTION; MACROPHAGE; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL WALL SKELETON; HUMANS; IMMUNOTHERAPY; MYCOBACTERIUM BOVIS; NEOPLASMS;

EID: 0034995057     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(01)00055-8     Document Type: Review

References (90)

1. Adjuvancity of mycobacterial cell wall
2. The mode of action of immuno-pharmacological adjuvants
3. Adjuvant activity of mycrobacterial fractions: I. Purification and in vivo adjuvant activity of cell wall skeletons of Mycobacterium bovis BCG, Nocardia asteroids 131 and Corynebacterium diphtheriae PW8
4. Biological active components from mycobacterial cell walls: I. Isolation and composition of cell wall skeleton and componet P3
5. Immunotherapy of cancer with BCG cell-wall skeleton and related materials
6. Immunologic and biochemical properties of bacterial fractions and related compounds with special reference to BCG cell wall skeleton and Nocardia rubra cell wall skeleton
7. Adjuvant immunotherapy of lung cancer with BCG cell-wall skeleton (BCG-CWS)
8. Nonspecific adjuvant immunotherapy on lung cancer with cell wall skeleton of Mycobacteria bovis, Bacillus Calmette-Guerin
9. A clinical trial of cell-wall skeleton of BCG in chemoimmunotherapy of acute leukemia
10. Postoperativeadjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton
11. Immunofriendly use of BCG-CWS-cell wall skeleton remarkably improves the survival rate of various cancer patients
12. Interferon as a marker for the effective cancer immunotherapy with BCG-CWS Wall skeleton
13. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan subunits
14. Muramyl peptides, immunomodulator, sleep factors, and vitamins
15. Muramyl dipeptide and derivatives
16. Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-l-alanyl-d-isoglutamine) and several analogs
17. Synthesis of long chain fatty acid esters of N-acetylmuramyl-l-alanyl-d-isoglutamine in relation to antitumor activity
18. Stimulation of nonspecific resistance to infection induced by 6 O-acyl muramyl dipeptide analogs in mice
19. Stimulation of nonspecific resistance to infection induced by muramyl dipeptide analogs substituted in the γ carboxyl-group and evaluation of Nα stearoyllysine
20. Anti-infectious activity of the synthetic muramyl dipeptide analogue MDP-Lys(L18)
21. Development of cytokine-inducer romurtide: Experimental study and clinical application
22. An acyl-MDP derivative, MDP-Lys(L-18) (Romurtide)
23. Muramyl tripeptide-phosphatidylethabolamine: A muramyl dipeptide drivatives with lipophilic properties
24. The immunomodulatory activities of acylpeptides
25. Pemelautide. From experimental results of clinical trials: An illustration
26. Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity
27. Syntex adjuvant formation
28. Polymorphonuclear leukocyte activation by a synthetic muramyl dipeptide analog
29. Stimulatory effect of romurtide on hematopoises in monkeys
30. Romurtide, a synthetic muramyl dipeptide derivative, promotes megakaryocytopoiesis through stimulation of cytokine production in nonhuman primates with myelosuppression
31. Oral application of romurtide, a synthetic muramyl dipeptide derivative, stimulates nonspecific reisitance to microbial infections and hematopoiesis in mice
32. Romurtide, a synthetic muramyl dipeptide derivative, accelerates peripheral platelet recovery in nonhuman primate chemotherapy model
33. Activation of the cytokine network by muroctasinas a remedy for leukopenia and thrombopenia
34. Therapeutic effect of miroctasin on cancer patients with leukopenia during radiation therapy
35. Restractive activity of muroctasin on leukopenia
36. Effects of muramyl dipeptide and its stearoyl derivatives on resitance to Sendai virus infection in mice
37. Effect of MDP-Lys(18), a derivative of MDP, on enhancing host resistance against Hantaan virus infection in new born mice
38. Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus
39. Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine
40. Studies on the virulence of tubercle bacilli. Isolation and biological properties of a constituent of virulent organisms
41. The chemical structure of the cord factor of Mycobacterium tuberculosis
42. Natural and synthetic trehalose diesters as immunomodulators
43. From natural products chemistry to immunopharmacology
44. Lethal and adjuvant activities of cord factor (trehalose-6.6-dimycolate) and synthetic analogs in mice
45. Lethal toxicity and adjuvant activity of synthetic trehalose monomycolate andrelated compounds
46. Chemical synthesis and biokogial activities of 6-6-di-O-mycoloyl-β,β- and -trehalose
47. Lethal toxicity and adjuvant activities of sysnthetic TDM and its related compounds in mice
48. Effective synthesis of four isomeric trehalose dicorynomycolates (TDCMs) and their immunoadjuvant activities
49. Inhibitoty effect of trehalose dimycolate (TDM) and its stereoisomeric derivatives, trehalose dicorynomycolates (TDCMs), with low toxicity on lung metastasis of tumour cells in mice
50. Ribi adjuvants: Chemistry, biology and utility in vaccines for human and veterinary medicine
51. Recognition of a lipid antigen by CD1-resticted αβT-cells
52. Structural requirements for glycolipid antigen recognition by CD1b-restricted T cells
53. CD1-restricted T-cell recognition of microbial lipoglycan antigens
54. CD1c restricts responses of mycobacteria-specific T cells. Evidence for antigen presentation by a second member of the human CD1 family
55. The CD1 family of lipid antigenpresenting molecules
56. How BCG led to the discovery of immunostimulatory DNA
57. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG: I. Isolation, physicochemical characterization and anti-tumor activity
58. A synthetic single-stranded DNA, poly(dG,dC), induces interferon a/b and g, augments natural killer activity and suppresses tumor growth
59. A Toll-like receptor recognizes bacterial DNA
60. Oligo-deoxyrihonucleotides with 5′-ACGT-3 or 5′-TCGA-3′ sequence induce production of interferons
61. Motifs in bacterial DNA trigger B-cell activation
62. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12 and interferon gamma
63. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity
64. A family of human receptors structurally related to Drosophila Toll
65. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling
66. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products
67. Molecular mechanisms of activation of the human innate immune system
68. Differential expression and regulation of Toll-like receptors (ThR) in human leukocytes:selective expression of TLR3 in dendritic cells
69. Microbial receptors: The host defense system across primates and invertebrates
70. Three novel mammalian Toll-like receptors: Gene structure, expression, and evolution
71. Cloning and characterization of a sub-family of human Toll-like receptors: hTLR7, hTLR8 and hTLR9
72. Human Toll-like receptors mediate cellular activation by Mycobacterium tuberculosis
73. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages
74. Cell-wall skeleton of BCG participates in a maturation step of human dendritic cells (DC); establishment of unique mature DC from immature DC
75. IFNg-producing ability in blood of patients with lung cancer: Production of IL-12 p40 and IL-18 in response to BCG-CWS
76. Immuno-friendly use of BCG-cell wall skeleton remarkably improves the survival rate of various cancer patients
77. Toll-Iike receptor family arid signalling pathway
78. Peptidoglycan portion in BCG-CWS participates in activation of human dendritic cells through Toll-like receptors
79. Bacillus Calmette-Guerin mycobacteria stimulate human blood dendritic cells
80. Interleukin 18 regulates both Th1 and Th2 responses
81. Human MDI homologue is a BCG-regulated gene product in monocytes: Its identification by differential display
82. Coordinated events during bacteria-induced DC maturation
83. Cancer immunotherapy with cell wall skeleton
84. The treatment of malignant tumors by repeated inoculations of erisipelas: With a report of ten original cases
85. For whom the bell tolls
86. Two receptor theory in innate immune activation: Studies on the receptors for bacillus Culmet Guillen-cell wall skeleton (BCG-CWS)
87. Innate immunity: The virtues of a monoclonal system of recognition
88. A Family of human receptors structurally related to Drosophila Toll
89. Cell activation and apoptosis by bacterial lipoproteins through tall-like receptor-2